Elevated Plasma Pentraxin 3 and Its Association with Retinal Vein Occlusion
Korean Journal of Ophthalmology
;
: 460-465, 2014.
Article
in English
| WPRIM
| ID: wpr-30317
ABSTRACT
PURPOSE:
To evaluate plasma pentraxin 3 (PTX3) in patients with retinal vein occlusion (RVO), and investigate the possibility of its role as a predictive biomarker.METHODS:
Nested case-control study. The study included 57 patients with RVO and 45 age- and gender-matched subjects without RVO as controls. Plasma PTX3 and C-reactive protein concentration were measured in both groups a posteriori from frozen samples by using an enzyme-linked immunosorbent assay kit.RESULTS:
The measured PTX3 value for the RVO group was 1,508 +/- 1,183 pg/mL (mean +/- standard deviation) and 833 +/- 422 pg/mL for the controls (p < 0.001). There was no significant difference in PTX3 levels between patients with central retinal vein occlusion and branched retinal vein occlusion (1,468 +/- 1,300 vs. 1,533 +/- 1,121 pg/mL; p = 0.818).CONCLUSIONS:
Our data seems to support the role of chronic inflammation and ischemia in the development of RVO. It is possible that PTX3 can be used as a diagnostic biomarker of RVO.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Retinal Vein Occlusion
/
C-Reactive Protein
/
Acute-Phase Proteins
/
Serum Amyloid P-Component
/
Enzyme-Linked Immunosorbent Assay
/
Biomarkers
/
Case-Control Studies
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
English
Journal:
Korean Journal of Ophthalmology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS